Multicenter, open-label, 24 week regimen of 8 mg pegloticase i.v. [intravenous] in symptomatic gout subjects who participated in previous studies of pegloticase i.v

Trial Profile

Multicenter, open-label, 24 week regimen of 8 mg pegloticase i.v. [intravenous] in symptomatic gout subjects who participated in previous studies of pegloticase i.v

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2011

At a glance

  • Drugs Pegloticase (Primary)
  • Indications Gout
  • Focus Adverse reactions; Registrational
  • Acronyms GOUT-3
  • Sponsors Savient Pharmaceuticals
  • Most Recent Events

    • 05 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Mar 2010 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
    • 28 Oct 2008 Planned end date (Dec 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top